Category: Federal Forum Posters
Purpose: The discovery and development of immunomodulatory agents, proteasome inhibitors and monoclonal antibodies in combination with high dose steroids have changed Multiple myeloma disease course significantly enough to almost be considered a chronic condition. Consequently, relapsed and refractory disease occurs. Monoclonal antibody-containing regimens such as daratumumab and elotuzumab, have become the standard of care for relapsed or refractory multiple myeloma and at this time are given until disease progression or unacceptable toxicity. However, the risk of infections with these agents is still unclear. Currently, there are no published studies assessing the infection rates with these monoclonal antibodies.
Methods: A retrospective cohort study will be conducted to evaluate the infection rates of treatment regimens consisting of either elotuzumab or daratumumab versus the same treatment regimens without elotuzumab or daratumumab. Patients ages 18 years or older with refractory or relapsed multiple myeloma being treated at any Veterans Affairs hospital across the United States between January 1, 2016 and January 1, 2018 will be assessed through the electronic medical record system. Patients who are pregnant, using a monoclonal antibody for any treatment other than multiple myeloma, have a preexisting chronic infection, or use of immunosuppressive therapy outside of cancer treatment were excluded from the study. The following data will be collected: Age, sex, race, weight, past medical history, treatment regimen, duration of treatment, white blood cells/neutrophils, creatinine clearance, temperature, type of infection, infection grade, mortality, hospitalization, length of stay, discontinuation, and treatment delay. All patients will be deidentified as data is collected and recorded. Baseline differences in characteristics and demographics will be evaluated using Chi-square or fisher’s exact test. Continuous variables will be evaluated using student’s t test. This study has been submitted and is currently pending for approval by the Institutional Review Board.
Results: not applicable
Conclusion: not applicable
Bradley Vincent– Pharmacy Resident, VA Ann Arbor Healthcare System, Plymouth, MI